

AMENDMENTS TO THE CLAIMS

This Listing of Claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims

H¹ Claim 1 (currently amended): A transgenic mouse comprising a genome comprising a) exactly one functional elastin gene and b) either one mouse elastin gene comprising a null mutation or no second elastin gene, wherein said mouse has an increased number of elastic lamellae.

Claim 2 (currently amended): A transgenic mouse comprising a genome with no functional elastin gene, wherein said mouse has arterial occlusion.

Claim 3 (currently amended): ~~A~~ An isolated mouse cell comprising a genome comprising a) exactly one functional elastin gene and b) one mouse elastin gene comprising a null mutation or no second elastin gene.

Claim 4 (currently amended): ~~A~~ An isolated mouse cell comprising i) a genome with no elastin gene or ii) a genome with a) elastin gene comprising a null mutation and b) no functional elastin gene.

Claim 5 (currently amended): A method to screen for drug candidates useful for treating humans with supravalvular aortic stenosis (SVAS), hypertension or atherosclerosis or useful for preventing atherosclerosis in humans, said method comprising administering said drugs to an ELN +/- mouse or ELN +/- human, wherein said ELN +/- mouse or said ELN +/- human comprises a genome with a) exactly one functional elastin gene and b) either one elastin gene

comprising a null mutation or no second elastin gene, wherein said ELN +/- mouse or said ELN +/- human has an increased number of elastic lamellae, wherein drugs which inhibit occlusion of arteries in said ~~organism~~ ELN +/- mouse or said ELN +/- human are said drug candidates.

Claims 6-8 (canceled).

Claim 9 (currently amended): A method to screen for a drug candidate useful for treating atherosclerosis, hypertension or supravalvular aortic stenosis (SVAS) in a human, said method comprising treating an ELN +/- mouse, ~~or~~ ELN +/- human, ~~or~~ ELN +/- mouse cells or ELN +/- human cells, wherein said ELN +/- mouse, ~~or~~ ELN +/- human, ~~or~~ ELN +/- mouse cells or ELN +/- human cells comprise a genome with a) exactly one functional elastin gene and b) either one elastin gene comprising a null mutation or no second elastin gene, wherein said ELN +/- mouse or said ELN +/- human has an increased number of elastic lamellae, with drugs and measuring synthesis of elastin RNA wherein a drug which increases synthesis of elastin RNA in said ~~organisms~~ ELN +/- mouse, said ELN +/- human, ~~or in~~ said ELN +/- mouse cells or said ELN +/- human cells is said drug candidate.

Claim 10 (currently amended): A method to screen for a drug candidate useful for treating atherosclerosis, hypertension or supravalvular aortic stenosis (SVAS) in a human, said method comprising treating ELN +/- mice or ELN +/- mouse cells, wherein said ELN +/- mice or ELN +/- mouse cells comprise a genome with a) exactly one functional elastin gene and b) either one elastin gene comprising a null mutation or no second elastin gene, wherein said mouse has an increased number of elastic lamellae, with drugs and measuring synthesis of elastin wherein a drug which increases synthesis of elastin is said drug candidate.

141
Claims 11-14 (canceled).